Citation Impact
Citing Papers
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Discovery, mechanisms of action and combination therapy of artemisinin
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Cancer is a Preventable Disease that Requires Major Lifestyle Changes
2008 Standout
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Immunology and molecular biology of Opisthorchis viverrini infection
2003
The multitude and diversity of environmental carcinogens
2007 StandoutNobel
Soy intake and cancer risk: A review of thein vitroandin vivodata
1994 Standout
Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
2002
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
2008 Standout
Hepatitis B Virus Infection: Epidemiology and Vaccination
2006 Standout
Ribavirin and Interferon Is Effective for Hepatitis C Virus Clearance in Hepatitis B and C Dually Infected Patients
2003
Liver cancer in Thailand. I. A case‐control study of cholangiocarcinoma
1991
Burden of liver diseases in the world
2018 Standout
Liver fibrosis – from bench to bedside
2003 Standout
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Review: Infectious Diseases and Coagulation Disorders
1999
Typhoid and Paratyphoid Fever: A 10-Year Retrospective Study of 41 Cases in a Parisian Hospital
2006
Cholangiocarcinoma
2008
The global health burden of infection‐associated cancers in the year 2002
2006 Standout
Lifestyle-related factors and environmental agents causing cancer: An overview
2007 StandoutNobel
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
2012
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Measuring reactive species and oxidative damagein vivoand in cell culture: how should you do it and what do the results mean?
2004 Standout
Opisthorchis viverrini: The carcinogenic human liver fluke
2008
Global cancer statistics
2011 Standout
Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology
2002
Schistosomiasis
2018 Standout
Helminths and malignancy
2009
Chronic hepatitis B
2007 Standout
Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma†
2006
Chronic hepatitis B: Update 2009 #
2009 Standout
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Fish-borne parasitic zoonoses: Status and issues
2005 Standout
Spectrum of Disease and Relation to Place of Exposure among Ill Returned Travelers
2006 Standout
Association of Nonalcoholic Fatty Liver Disease With Components of Metabolic Syndrome According to Body Mass Index in Korean Adults
2012
Epidemiology of cholangiocarcinoma: An update focusing on risk factors
2009
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Children with hepatitis C
2002
Cross‐sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high‐risk area in northeast thailand
1994
Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection
1999
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
2010
Severe falciparum malaria
2000
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
2006 Standout
Global Epidemiology of Hepatitis B Virus
2004
Investigation on Subclinical Aspects Related to Intestinal Parasitic Infections among Thai Laborers in Taipei
2006
Fascioliasis and other plant-borne trematode zoonoses
2005 Standout
Opisthorchis viverrini and opisthorchiasis: a historical review and future perspective
2003
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020
2020
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
2017
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
The treatment of complicated and severe malaria
2005
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma.
1994
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
2011
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
Roles of liver fluke infection as risk factor for cholangiocarcinoma
2014
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
Epidemiology of Opisthorchis viverrini
2003
Global cancer statistics, 2012
2015 Standout
Nonalcoholic Fatty Liver Disease
2015 Standout
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
1996 Standout
Phytochemical Screening and Antioxidant Activities of Some Selected Medicinal Plants Used for Malaria Therapy in Southwestern Nigeria
2008 Standout
Works of C Pramoolsinsap being referenced
Salmonella hepatitis
1998
Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV‐ or hepatitis C virus‐related chronic liver diseases in Thailand
2000
Opisthorchis viverrini infection in rural and urban communities in northeast Thailand
1987
Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway
1994
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
2011
Opisthorchis viverrini infection and cholangiocarcinoma
1985
Genotypes and subtypes of hepatitis B virus in Thailand.
1998
Prevalence of anti-HCV antibody in family members of anti-HCV-positive patients with acute and chronic liver disease.
1992
Prevalence and outcomes of HBV and anti-HCV seropositive patients with chronic liver disease and hepatocellular carcinoma.
1992
Coinfections with hepatitis g and/or c virus in hepatitis B-related chronic liver disease.
1999
Hepatitis B problem in Thailand.
1986
[701] PENTOXIFYLLINE FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): A RANDOMIZED, PLACEBO-CONTROLLED STUDY
2007